Abstract
Bristol-Myers Squibb will release its third-quarter 2026 results before market open on October 29, 2026 (Pre-MKt), with consensus pointing to year-over-year revenue growth and pressure on EBIT and adjusted EPS.Market Forecast
Consensus expects Bristol-Myers Squibb’s third-quarter revenue to be 12.74 billion US dollars, up 7.80% year over year, EBIT at 3.34 billion US dollars, down 7.19% year over year, and adjusted EPS at 1.20, down 20.69% year over year; margin forecasts are not provided by the consensus collected. Based on recent product updates, revenue strength is anticipated to be anchored by Eliquis (apixaban) and Opdivo (nivolumab), with incremental growth from newer launches and cell therapy.Within the core portfolio, Eliquis remains the largest contributor and Opdivo supports oncology momentum; growth assets Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Reblozyl (luspatercept), and Opdualag are expected to continue scaling, with Breyanzi and Camzyos showing meaningful quarter-over-quarter traction in recent periods. The most promising near-term contributor among growth assets is Breyanzi, which generated 484.00 million US dollars last quarter; year-over-year growth by product was not disclosed in the collected data.
Last Quarter Review
In the previous quarter, Bristol-Myers Squibb reported revenue of 12.97 billion US dollars (up 5.74% year over year), a gross profit margin of 71.39%, GAAP net profit attributable to the parent company of 3.32 billion US dollars, a net profit margin of 25.57%, and adjusted EPS of 2.04 (up 39.73% year over year).Net profit improved on a quarter-on-quarter basis by 23.91%, aided by resilient gross margin and disciplined operating expense control relative to revenue growth. The main business mix was led by Eliquis at 4.48 billion US dollars and Opdivo at 2.49 billion US dollars, while newer franchises delivered expanding contributions: Breyanzi at 484.00 million US dollars and Camzyos at 416.00 million US dollars; specific year-over-year product-level growth was not disclosed.
Current Quarter Outlook
Main Business Drivers This Quarter
Revenue this quarter is expected to grow year over year to 12.74 billion US dollars, supported by core products Eliquis and Opdivo. Eliquis remains the largest single product and typically benefits from broad cardiovascular use, while Opdivo’s continued contribution across multiple tumor types supports oncology revenue stability. The consensus does not publish a gross margin forecast, yet the prior quarter’s 71.39% gross margin sets a high baseline; management commentary on pricing, payer dynamics, and product mix will be closely watched to gauge the margin trajectory.On earnings, consensus indicates EBIT will decline 7.19% year over year to 3.34 billion US dollars and adjusted EPS will decline 20.69% year over year to 1.20. This disconnect between revenue growth and EPS implies a potential mix shift toward products with different margin characteristics, increased R&D related to late-stage programs, and possibly higher SG&A linked to launches and market expansion. The quarter’s narrative will likely hinge on how well Bristol-Myers Squibb translates topline momentum into operating leverage, and whether expense timing and investment phasing can be moderated to protect EPS.
Operationally, sequential dynamics will also matter: the prior quarter delivered adjusted EPS of 2.04 and EBIT of 5.12 billion US dollars, both up meaningfully year over year, giving the company a strong run-rate to lap. If underlying demand for Eliquis and Opdivo remains steady and price/mix effects do not deteriorate, the company may keep revenue above consensus while still reporting year-over-year declines in profitability, consistent with current estimates.
Most Promising Growth Segment
Breyanzi continues to show solid scaling in cell therapy with 484.00 million US dollars last quarter, and its commercial ramp positions it as a leading near-term growth lever. Beyond Breyanzi, Camzyos contributed 416.00 million US dollars last quarter and recently received expanded US approval to treat pediatric patients with a specific heart condition on October 01, 2026, which may broaden the eligible patient pool and support incremental demand. Together with Opdualag and Reblozyl, these assets diversify revenue away from legacy products and offer additive growth vectors as uptake broadens and label expansions progress.The third quarter’s sales mix may therefore lean more toward these growth franchises, even as absolute dollar contributions still trail Eliquis and Opdivo. Unit demand, launch cadence, and reimbursement clarity are crucial to sustaining momentum; management’s comments on manufacturing capacity and patient access for cell therapy will be particularly relevant for Breyanzi. With consensus forecasting revenue growth but EPS contraction, a larger revenue share from growth assets could be welcomed by investors who prize long-term durability, provided there is a clear path to margin stabilization as volumes scale.
Pipeline-linked catalysts provide further support for confidence in this growth cohort. On October 12, 2026, the company reported that an interim analysis of RayzeBio’s radiopharmaceutical therapy RYZ101 met its primary endpoint, strengthening visibility in radiopharmaceuticals. These developments, while not immediate revenue drivers, reinforce the longer-term trajectory of the growth portfolio and could influence sentiment around near-term commercial assets through perceived platform validation.
Key Factors Impacting the Stock This Quarter
The primary factor influencing the stock near the print is the divergence between revenue growth and earnings compression: consensus expects revenue up 7.80% year over year but EBIT down 7.19% and adjusted EPS down 20.69%. Investors will parse whether this reflects short-term investment timing, product mix effects, or competitive dynamics that can be managed through cost discipline and launch efficiency. If management frames the EPS pressure as transitory and provides clear guidance on margin recovery, sentiment may improve even if near-term profitability is constrained.Product-level momentum and news flow are the second key driver. On October 12, 2026, Bristol-Myers Squibb said the phase 3 ALOFT-IPF trial for admilparant met its primary endpoint at the 60 mg dose, while the 120 mg dose slowed lung function decline without statistical significance, and UBS commented that the program remains viable with competitive forced vital capacity benefit expectations. Positive updates on ongoing registrations and label expansions, together with the October 01, 2026 Camzyos pediatric approval, could enhance the narrative for sustainable growth outside the largest mature brands. Any upside commentary for Eliquis and Opdivo demand will also be supportive.
Third, guidance and color on operating expenses will be closely watched. The prior quarter’s net profit rose 23.91% sequentially on strong gross margin, but this quarter’s consensus implies less operating leverage and lower EPS. Investors will look for granularity on R&D pacing across late-stage programs and targeted SG&A spend to support launches, particularly in cell therapy and cardiovascular franchises. A well-telegraphed expense path, paired with clarity on gross-to-net adjustments and pricing, can help bridge the gap between topline growth and EPS goals.
Analyst Opinions
Cautious and neutral views dominate recent sell-side commentary, with bearish/cautious notes outnumbering bullish calls by roughly 80% to 20% over the past several months. RBC Capital maintains a Hold rating and recently suggested Bristol-Myers Squibb could beat Q3 revenue estimates, pointing to stronger-than-expected sales from Eliquis and Revlimid alongside growth products including Breyanzi; nevertheless, the rating stance remains neutral, emphasizing revenue upside with profitability and pipeline execution as watch points. Cantor Fitzgerald (Hold, 53 US dollars target), Scotiabank (Hold, 60 US dollars target), and multiple RBC reiterations (Hold, 64 US dollars target) reflect the cautious tilt.Leerink Partners downgraded Bristol-Myers Squibb to Market Perform and cut its price target to 59 US dollars on October 05, 2026, citing valuation recalibration and execution timing around the pipeline as core reasons for restraint. HSBC reduced its target to 60 US dollars on October 19, 2026, and Wells Fargo cut to 60 US dollars on October 13, 2026, while BofA Securities lowered its target to 66 US dollars on October 09, 2026; these moves collectively signal tempered expectations on near-term return profile amid earnings compression. Morgan Stanley’s recent adjustment reported a low target in the 41 US dollars range, underscoring how some analysts see downside risk tied to margin visibility and the cadence of new product adoption.
Against that backdrop, isolated bullish voices remain present but in the minority. Truist Financial reiterated a Buy with a 70 US dollars target, and Jefferies raised its target to 76 US dollars, both indicating confidence in the commercial portfolio and late-stage assets. Yet, these views coexist with the broader cautious sentiment due to consensus forecasts for adjusted EPS down 20.69% year over year and EBIT down 7.19% year over year in the current quarter.
The majority viewpoint expects Bristol-Myers Squibb’s headline revenue to be resilient but earnings metrics to be pressured by product mix and ongoing investment into launches and the pipeline. Cautious analysts will look for three validations to shift stance: confirmation of revenue outperformance versus the 12.74 billion US dollars consensus, concrete evidence of margin stabilization despite the forecasted EPS decline, and clear, timely updates on late-stage programs such as admilparant and radiopharmaceutical initiatives like RYZ101. If management provides specific milestones that delineate when EPS pressure could ease and how operating leverage will improve, some of the recently reduced targets could be revisited in subsequent quarters.
In summary, the prevailing institutional perspective is cautious: revenue momentum appears intact, yet near-term profitability and EPS optics are central to valuation debate. Delivering a revenue beat, communicating expense discipline with credible margin recovery paths, and sustaining positive pipeline updates would address the majority’s reservations and could pivot sentiment more constructively after October 29, 2026.
Comments